Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799978 | 0.88 | PARP1 (0.43) | HCRTR1HCRTR2MAP4K1TRPV1 | |
| SCHEMBL12350593 | 0.85 | KDM1A (0.42) | HCRTR1HCRTR2TRPV1PDE10ADHODH | |
| SCHEMBL12350624 | 0.82 | TRPV1 (0.42) | HCRTR1HCRTR2TRPV1BACE1 | |
| SCHEMBL12350623 | 0.82 | TRPV1 (0.42) | HCRTR1HCRTR2TRPV1BACE1 | |
| SCHEMBL12350617 | 0.82 | TRPV1 (0.42) | HCRTR1HCRTR2TRPV1BACE1 | |
| SCHEMBL12350620 | 0.82 | TRPV1 (0.42) | HCRTR1HCRTR2TRPV1BACE1 | |
| SCHEMBL12350188 | 0.82 | TRPV1 (0.42) | HCRTR1HCRTR2TRPV1BACE1 | |
| SCHEMBL1797327 | 0.82 | HCRTR1 (0.39) | HCRTR1HCRTR2TRPV1PDE10A | |
| SCHEMBL12350598 | 0.82 | HCRTR1 (0.39) | HCRTR1HCRTR2MAP4K1TRPV1BACE1 | |
| SCHEMBL12350621 | 0.81 | TRPV1 (0.42) | HCRTR1HCRTR2TRPV1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | HCRTR1 3055/4885HCRTR2 3386/4885MAP4K1 2256/4885 |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | HCRTR1 3055/4885HCRTR2 3386/4885MAP4K1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.